Data from EMD Serono's Multiple Sclerosis Portfolio to be Presented at the 62nd Annual Meeting of the American Academy of Neurology

New data on established therapy Rebif^® and on investigational therapy Cladribine Tablets to be presented at AAN underscore EMD Serono’s commitment to multiple sclerosis care and research

Press Release Source: EMD Serono, Inc. On Wednesday March 31, 2010, 8:00 am EDT

ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company’s multiple sclerosis (MS) portfolio of approved and investigational treatments will be presented at the 62^nd Annual Meeting of the American Academy of Neurology (AAN) taking place April 10 to 17, in Toronto, Canada. The data presented will focus on Rebif^® (interferon beta-1a), an established therapy for relapsing forms of MS, and Cladribine Tablets, a potential oral therapy for relapsing forms of MS currently under regulatory review in a number of countries.

“We have made a commitment as a leading company in this field to advance the treatment of multiple sclerosis and the underlying science,” said Bernhard Kirschbaum, PhD, Executive Vice President, Global Research and Development at Merck Serono, a division of Merck KGaA, Darmstadt, Germany. “The data presented at the upcoming AAN meeting will further contribute to the existing body of knowledge about Rebif^® and Cladribine Tablets, as well as to a greater understanding of the disease.”

The following abstracts have been accepted for presentation at the 62^nd AAN Annual Meeting:

>> CLICK to read these abstracts and more

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients

Information provided by Rusty
Wow and Yes, this will take place in The USA
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

This study is not yet open for participant recruitment.

Verified by The Vascular Group, PLLC, March 2010

The purpose of this Study is to evaluate safety, feasibility and efficacy of percutaneous transluminal angioplasty in treating extracranial venous obstructive lesions, and its influence on the clinical outcomes of Multiple Sclerosis (MS) patients.

Patients enrolled in the study will have a diagnosis of Multiple Sclerosis diagnosed according to the revised McDonald Criteria (MD) criteria, and will meet the eligibility criteria.

Click here to continue to review this information from the ClinicalTrials.gov website

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

MS Information in Spanish - Información de E.M. en Español

Información en Español

Bienvenidos a este su centro de información sobre la esclerosis múltiple (EM).

Aquí hallará información sobre diagnóstico y tratamientos, manejo de síntomas y asuntos laborales, así como información para cuidadores y niños. También hallará transmisiones educativas a través de la Internet, libros y enlaces a otros sitios educativos en la Internet.

Source: National MS Society

CLICK to review en Español - Clique Aqui para leer y escuchar en Español

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Old Theories about Multiple Sclerosis (Like Aspartame) That Have Been Disproved

Over the years, people have suggested many different causes for MS. Here are some of the most popular theories that have been proved incorrect:

• Owning a dog or other small pet
  Some years ago, canine distemper, a virus carried by dogs, was proposed as a cause of MS, but research has since ruled out household pets as the culprit.
• Allergies
  There is no evidence that MS is triggered by a reaction to a specific environmental allergen. Since allergies are common in the general population, allergies can occur in a person with MS.
• Exposure to heavy metals
  Although poisoning with heavy metals such as mercury, lead or manganese can damage the nervous system and produce symptoms such as tremor and weakness, both the process and the symptoms are different from what occurs in MS. There is no evidence that heavy metal exposure causes MS.
• Physical trauma
  A 1999 report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, based on a comprehensive study of the literature on the subject, concluded that "the evidence supports no association between physical trauma and either MS onset or MS exacerbation." Read their report in the journal Neurology or read more about trauma and MS.
• Aspartame
  No scientific evidence supports the claims on several Web sites that aspartame, an artificial sweetener used in many diet soft drinks and other foods, causes MS.
  

Source: National MS Society - click

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Scientists find there may be two forms of multiple sclerosis

Information reported to the editor of this blog by Karen H in Ft. Myers, Fl.

March 29, 2010

By Val Willingham - CNN Medical Producer

Scientists and doctors who study multiple sclerosis know, as of now, one of the best way to treat the condition is with beta-interferon. But over the years, the drug's effectiveness has been lukewarm in some people causing a third of all MS patients who are on the drug to suffer from uncomfortable flu-like side effects. Many can't handle it and so far, researchers have never figured out why.

Now scientists from Stanford University School of Medicine may have discovered that there are actually two kinds of multiple sclerosis and that each reacts differently to the standard treatment.

Researchers know multiple sclerosis is triggered when immune cells, called T cells, attack the myelin sheathing, which insulates neurons in the body. Healthy myelin sheathing is essential for the nervous system to function properly. When this material is attacked, it can cause serious symptoms including paralysis and blindness in those with MS.

In this study, published in the current issue of Nature Medicine, researchers established animal models of multiple sclerosis by injecting mice with myelin into their immune systems, causing it to attack the animals' own myelin nerve-cell coatings, much as MS attacks a human being’s. By looking at these animals and treating them with beta-interferon and then testing their blood the researcher found there were actually two different types of MS, caused by different patterns of T cells in the body. So what works for one, doesn't necessarily work for the other.

The researchers found that beta-interferon improved the condition of animals who had MS caused by gamma-interferon-secreting T cells, but made the symptoms worse in those mice whose MS was caused by IL-17-secreting T cells.

Intrigued, the investigators turned to humans. One of the study's authors, Dr. Brigit deJong, had previously been involved in research in Amsterdam in which multiple sclerosis patients were treated with beta-interferon and closely followed. The Stanford group obtained blood samples taken from 26 of these patients both before and about two years after the initial treatment. Without knowing which samples came from patients who had responded well or poorly to beta-interferon treatment, they went about measuring IL-17 levels in those samples. The human results were much like the animal models. Those with high amounts of IL-17 T cells had had negative reactions to beta-interferon.

"By making these distinctions in large human studies, people with multiple sclerosis might someday be able to take a simple blood test to see whether they are likely to respond to treatment with the standard multiple-sclerosis therapy." says senior study author Lawrence Steinman, M.D. of the Neurology and Neurological Sciences Department at the Stanford University School of Medicine.

If an inexpensive test can be developed to detect IL-17 in humans, MS patients and their doctors will know whether beta interferon is or isn't going to work. "For those who don't have the IL-17 T cells," notes Steinman, "those patients can receive beta-interferon and probably not in a diluted form but in a higher dose, which will help them better fight their illness."

According to the National Multiple Sclerosis Society MS affects 400,000 people in the United States. Dr. Patricia A. O'Looney, vice president of biomedical research for the National Multiple Sclerosis Society, says the new research is very exciting. "Obviously this will need more testing in human subjects," explains O’Looney, "But this is a positive step in the right direction to helping to treat MS and other autoimmune conditions."

Posted by: Val Willingham - CNN Medical Producer

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Multiple Sclerosis Telephone Support Group for Newly Diagnosed (within 2 years)

Telephone Support Group for Newly Diagnosed (within 2 years)

For South, North and Central Florida

Date: Wednesday, March 31st, 2010

Time: 7:00 PM to 8:00 PM

*Please call-in 5 minutes before start time

Topic: Communication and Maintaining Relationships

Call in number: 1-800-910-3597

Passcode: 24906202

Facilitator: Susan Dorne, OT

Contact information:

email: leseth143@aol.com

Subject: Support Group

The National MS Society: 1 800 FIGHT MS

Support needed to help 'MS Views and News' to educate

'MS Views and News' is asking for your support

Please use this Pledge card to help us to provide future education programs,

with a donation in the amount of:

___ $ 10.00

___ $ 25.00

___ $ 50.00

___ $ 100.00

___ $ 250.00

___ $ other

Make a check payable to: MS Views and News, Inc.

and mail to: 777 NW 72nd Ave. - SUITE 3005 - Miami, Fl. 33126

or visit: www.donations.msviewsandnews.org to make a secure online donation

Thanking you in advance for helping us to educate those affected by MS

"MS Views and News" is a 501©(3) organization as recognized by the Internal Revenue Service

~~~~~~~~~~~~~~~~~~~~~~

.

Researchers Find First Bio-Marker For MS

One Step Closer to Personalized Medicine
March 29, 2010

Researchers at the University of Alabama at Birmingham (UAB) have found the first bio-marker for multiple sclerosis (MS) that might predict which patients will respond to a standard therapy and which will not.

In findings published online March 28 in Nature Medicine, the UAB team, in a joint effort with researchers at Stanford University, discovered that patients with a particular type of T helper immune cells responded well to interferon-ß, the usual first-line therapy for the disease, while those with a different T helper immune-cell type either did not respond or experienced worsening symptoms.

"Interferon-ß is typically the first therapeutic choice for most MS patients, but there is a subset of about 30 percent of patients for whom it does not work and may make the patient worse," said Chander Raman, Ph.D., associate professor in the Division of Clinical Immunology and Rheumatology and lead investigator of the study. "Our findings, in both animal and human models, indicate that the type of T helper cell present is the determining factor in predicting whether interferon-ß will be effective."

Raman suggests this might be another rung on the ladder leading to personalized medicine, in which therapies are based on an individual's physiology and genetic makeup and the nature of disease.

"When our findings are verified in an expanded human trial, a simple blood test could be used to determine which type of T helper cell is predominantly responsible for the disease in an MS patient, enabling clinicians to provide the proper therapy from the beginning of treatment and eliminate the guesswork," Raman said.

Raman's team, along with the team at Stanford lead by Lawrence Steinman, Ph.D., examined T helper Type 1 cells and T helper Type 17 cells in an animal model for multiple sclerosis. Both Th1 and Th17 cells are major initiators of MS and important in disease severity. The researchers found that interferon-ß was effective in mice with disease initiated by Th1 cells, but worsened disease initiated by Th17 cells. The findings were replicated with striking consistency in analysis of human-patient serum with relapsing-remitting multiple sclerosis, the most common form of the disease.

"This research reinforces the concept that diseases have certain signatures that help define their origin and give us glimpses of how they manifest in our bodies," said Raman. "The more we understand these signatures, the more likely we will be able to intervene at a critical junction and design and provide therapies that lessen or cure disease."

The research was supported by grants from the National Multiple Sclerosis Society and the National Institutes of Health.

The UAB team consisted of Raman, Patrizia De Sarno and Rodrigo Naves. The team led by Steinman was made up of Robert Axtell, Roopa Bhat, May Han, Franklin Zhong, Jim Castellanos, Robert Mair, Athena Christakos, Ilan Kolkowitz, and Liat Katz from Stanford University; others participating were Brigit de Jong from Radboud University Nijmegen Medical Center, the Netherlands; Laura van der Voort, Joep Killestein and Chris Polman from VU University Medical Center, the Netherlands; and Katia Boniface and Rene de Waal Malefyt from Schering-Plough Biopharma.

About the UAB Division of Clinical Immunology and Rheumatology

The UAB Division of Clinical Immunology and Rheumatology is internationally recognized and dedicated to pursuing new knowledge and translating research findings into more effective diagnosis and treatment of patients with rheumatic diseases.

Source
University of Alabama at Birmingham

---

Article URL: http://www.medicalnewstoday.com/articles/183837.php

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

AN MS Patient's Journal continues on His LIBERATION TREATMENT

Written by Mitch - Saturday, March 27, 2010

CCSVI- Diagnosis and Treatment Log Entry #7

In Log Entry #6 I wrote about what the experience was like for me during the actual CCSVI procedure. Here, in Log Entry #7, I’ll get into the details about the abnormalities that were found, and the actions taken to correct them. To catch up on my complete CCSVI Diagnosis and Treatment log, click here (and then scroll down).

What an amazing experience it was.

Right Internal Jugular

An angiogram, which is an X-ray test using a special dye and camera to take pictures of the blood flow in the vein, was performed in the right internal jugular vein. This revealed a short segment stenosis adjacent to the confluence of the brachiocephalic vein. The diameter reduction associated with this stenosis was approximately 60%. The more important number, relative to flow restriction, is the cross sectional area reduction which in this case was approximately 85%.

Multiple collateral veins were noted at this location. Collateral veins indicate attempts by the body to establish bypass flow around an obstruction. Dr. Sclafani inserted the intravascular ultrasound device (IVUS) and confirmed the stenosis. A balloon was inserted, and the vein was dilated multiple times. Another angiogram was performed after dilation which indicated improved flow, diminished flow through collaterals, and no stenosis. Note that the nominal diameter of this blood vessel was 12 mm. Dr. Sclafani prefers to slightly over-dilate the vessel in these instances, and so a 14mm x 4 cm balloon was used.

CLICK to continue from Mitch's blog

~~~~~~~~~~~~~~~~~~~~~~~~~~~

Head-to-Head Study Comparing TYRABRI To Copaxone And Rebif

March 26, 2010

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis (RRMS). The study, called SURPASS, is expected to enroll 1,800 patients in 27 countries and provide direct comparative data of different treatment options for RRMS patients who experience breakthrough disease activity.

"Despite being on therapy, many MS patients still experience disease progression, resulting in loss of physical abilities and permanent damage to the central nervous system," said Richard Rudick, M.D., chair of the SURPASS trial advisory committee and director of the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic. "Currently, there is limited data to inform decisions about how to switch in patients who have disease activity while on therapy. The goal of the SURPASS study is to provide that data so physicians can improve treatment decisions and outcomes for their MS patients."

A significant number of MS patients continue to experience clinical relapses and disease progression despite treatment with disease-modifying therapies such as Copaxone and Rebif. The SURPASS study, a large, well-controlled comparative trial of MS treatments, will evaluate switching to TYSABRI versus staying on or switching between Copaxone and Rebif and determine whether early use of TYSABRI in the treatment algorithm ultimately leads to better outcomes.

"TYSABRI is a compelling treatment option that is bringing hope to many MS patients," said Alfred Sandrock, M.D., M.P.H., senior vice president of neurology research and development at Biogen Idec. "By evaluating TYSABRI against other MS treatments, our goal is to provide the data needed to make better treatment decisions and improve patients' lives."

"We believe the SURPASS study has the potential to improve the way MS is treated," said Carlos Paya, M.D., Ph.D., president at Elan. "Despite significant advances in treatment, the unmet medical need for many MS patients remains great and this study supports our commitment to continuing to advance the standard of care in MS."

Continue reading from Medical News Today

*

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Chronic Cerebrospinal Venous Insufficiency (CCSVI) updates

Chronic Cerebrospinal Venous Insufficiency (CCSVI)

Drs. Kim and Kabutey are leading new studies on Chronic Cerebrospinal Venous Insufficiency (CCSVI), a new treatment for multiple sclerosis (MS). Initial research has shown an improvement on MS symptoms.

To read more information on CCSVI, click here to review various other links.

*

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

CCSVI NEWS : After Patients Push for Experimental Treatment, Doctors Conclude It's Too Risky

MS Program Halted Amid Controversy

March 25, 2010

By THOMAS M. BURTON

Stanford University vascular specialist Michael D. Dake has done pioneering work at the hospital's cardiac-catheterization labs, like fixing certain aortic aneurysms once thought untreatable.

But Dr. Dake's experimenting touched off a furor at the university recently when—based on preliminary research by an Italian surgeon—he inserted metal stents into the internal jugular veins of multiple sclerosis patients. Doctors are generally allowed to adapt for new uses devices, like stents, that have received Food and Drug Administration approval.

In December, Dr. Dake's 40-patient MS stenting program was shut down, according to Stanford officials. A number of patients treated by Dr. Dake had reported improvements in their symptoms following the procedure. However, one patient died of a brain hemorrhage on the way home from treatment and another had to undergo life-saving emergency surgery. Neurologists from Stanford and the University of California, San Francisco, had protested to Stanford medical school officials that the procedure was too untested to be used in people. It's not clear which factors contributed to the program's ending.

Continue reading by clicking here to read this Wall Street Journal report

Also to see a diagram of the jugulars involved with this procedure

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Getting rid of those pesky Needles

Often it's asked of me where people can dispense of their needles when their doctors no longer take them.

The only answer for you, is to call your local waste management representatives (those who pick up your trash). - I am sure they will have the answer for you, depending on where you live.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Adult Stem Cell Therapy information

Stem cell research is still one of the topics for a good debate when it comes to the science or researching of ways to help mankind. The biggest issue was with the use of the embryonic stem cells which are now commonly used in research methods because government agencies are aware of their benefits for the human race. Trying to fight disease and cure cancers is becoming easier with the use of stem cell research so those people who have protested against these procedures are going to lose out if they decide to boycott the programs.

The miracles that stem cell research has provided over the last few years have been widely publicized. The fact that after all the media scare mongering the research was finally stopped because of the way the research had started to pay off dividends. Once certain parts of the research had been perfected then this was introduced into the common medical community so that everyone could benefit from the advantages.

Found in common cells the adult stem cells can be retrieves simply through skin or flesh samples and then extracted from the rest of the debris. By using the cells for different studies and research endeavors, scientists have started to make numerous discoveries which can be used to help save lives.

Read More at: www.adultstemcells.netW.ADULTSTEMCELLS.NET

*

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

For those with MS: Make Injections More Pleasant With a Ritual

written by (about.com's) Julie Stachowiak, Ph.D.,

For many of us who use the multiple sclerosis disease-modifying drugs known as the CRAB drugs (Copaxone, Rebif, Avonex and Betaseron), the injection process stands out as the worst part of our day. If you had someone describe his “injection ritual” step-by-step, he may say that the first step is to spend a couple minutes dreading the injection, step two is to give the injection, step three is to end the sequence by hating the injection process and MS altogether. Developing a ritual around your injection that is more pleasant than the one just described may make the process go more smoothly.

Click here to continue from the Julie's blog

*

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Remain up-to-date and Informed with Multiple Sclerosis News and Information.

If not yet receiving the "Stu's Views and MS Related News", weekly M.S.

e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org.

- Thank you -

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

If You have Multiple Sclerosis, Is Your Neurologist A Fit For You?

Written By Karen - The Self Healing Coach

March 24, 2010

If you’ve got MS, your neurologist plays an extremely important role in your life. For many of you, these visits are your only direct, in-person contact with a medical expert on MS. In other words, this person is in a position of massive authority – a position to significantly influence your attitude about your illness and your choices. (Even if you only meet your doc a few times a year – sometimes especially because of that.)

This person’s got a whole lotta sway. And that’s fine – as long as you’ve chosen the right doctor for you. Doctors hold so much authority in our culture that sometimes we may forget who is working for who. Your doctor is your employee, not the other way around, and if you’re not satisfied with his performance, you may and darn well should fire him and find someone better. I have a client who wanted to fire her doctor but she was afraid to hurt his feelings and afraid that he might call her to find out why. I asked her what she was more afraid of – experiencing the discomfort of facing someone squarely and telling them an unpleasant truth, or putting her health – her very life – in the hands of the wrong person.

Today I want to ask you a few questions to jog your thinking about your doctor and whether or not he or she is the right one for the job. Remember – inviting someone in to help you heal is a sacred role. Your doctor should honor that and honor you.

Click to read the doctor quiz and more

######################################

Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - Thank you

######################################